

Time	Gustav Mahler V Level 3	
8:00 – 8:50	Reports of the ELN Workpackages 4 – 9	Chair: B. Simonsson / N. Gökbüget
10'	MPN (WP9)	T. Barbui
10'	MDS (WP8)	T. de Witte
10'	CLL (WP7)	P. Ghia
10'	ALL (WP6)	D. Hoelzer
10'	CML (WP4)	A. Hochhaus
9:00 – 9:50	Reports of the ELN Workpackages 14, 5, 10, 11, 13	Chair: M.C. Béné / T. Haferlach
10'	SCT (WP14)	D. Niederwieser
10'	AML (WP5)	G. Ossenkoppele
10'	Diagnostics (WP10)	M.C. Béné / G. Zini
10'	Cytogenetics (WP11)	D. Haase
10'	Next generation sequencing (WP13)	T. Haferlach
10:00 – 10:30	<b>Coffee break and Group-photo (Foyer – Level 3)</b>	
10:30 – 11:00	ELN Merit Awards	Chair: R. Hehlmann
3'	Introduction for Andreas Hochhaus	N. Cross
3'	Introduction for Klaus van Ackern	R. Hehlmann
3'	Introduction for Dieter Hoelzer	J. Rowe
3'	Introduction for Theo de Witte	E. Hellström-Lindberg
3'	In memoriam David Grimwade	A. Reiter
11:00 – 13:00	Key-note lectures	Chair: D. Hoelzer / S. Sauße
20'	Prognostic indicators of successful TKI-discontinuation – Results of EURO-SKI	S. Sauße
20'	New MDS-Right guidelines – About what and for whom?	E. Hellström-Lindberg
20'	The path to cure of CLL	P. Ghia
20'	Big data management in leukemia	M. Dugas
20'	HARMONY – A big data platform for hematologic malignancies	J.M. Hernandez
20'	ELN-recommendations on the management of adverse TKI events	J.L. Steegmann
13:00 – 14:00	<b>Small farewell lunch (Foyer – Level 3)</b>	
14:00 – 17:00	Workshop: G. Mahler III Understanding modern statistical methods applied to clinical trials in leukemia	Chair: J. Guilhot / M. Pfirrmann
25'	The interpretation of the p-value – Fallacies and limitations	M. Pfirrmann
25'	Adaptive designs: drop a loser, pick the winner	J. Guilhot
25'	Sample size estimation for survival data	M. Lauseker
25'	Can claims data of patients hospitalized with leukemia be useful?	T. Pavlík
25'	Network meta-analysis	V. Hoffmann
25'	Autologous transplantation as time-dependent factor for survival of patients with ALL: Study data and simulation model	S. Kulikov

### General Information

#### Registration and information

Registration is at the information desk which is located on the third floor of the Rosengarten Congress Centre. Please, sign in upon your arrival at the Congress Centre every day. You will find ELN-employees at the information desk to assist you and to answer any questions you may have.

#### Internet

SSID: mconweb\_basis  
User name: 2017\_KW\_005  
Password: 790490697

#### Luggage

We have no facilities to store luggage. You could leave your luggage at your own risk at the cloakroom near the information desk.

#### Mannheim

We provide a map of the city Mannheim with tram lines.

#### Presenters of data, key note speakers

In order to have a smoothly running symposium of high quality, please, copy your presentation to the Media Desk before the start of the session or send it by e-mail to: gabriele.bartsch@medma.uni-heidelberg.de.


#### Travel costs reimbursement for members of the ELN or KNL

We do no longer provide a paper version of the reimbursement forms. This is due to past experiences of time-consuming and costly errors regarding contact and bank details. Reimbursement forms will be sent via e-mail to all entitled ELN members (reimbursement according to our current regulations). Please, complete the reimbursement claim form electronically and not handwritten. Thank you.

13:00 – 14:00	Small farewell lunch (Foyer – Level 3)	
14:00 – 17:00	HARMONY G. Mahler II Big data in hematologic management	Chair: J.M. Hernandez

Prof. Dr. Dr. h.c. Rüdiger Hehlmann  
PD Dr. Susanne Sauße  
III. Medizinische Universitätsklinik  
Medizinische Fakultät Mannheim der Ruprecht-Karls-Universität Heidelberg  
Pettenkoferstr. 22 | D-68169 Mannheim  
Germany  
Fon: +49 | 621 | 383 | 69 65 / 69 66  
Fax: +49 | 621 | 383 | 69 69  
E-Mail: nmc@leukemia-net.org

www.leukemia-net.org



## 14. Annual Symposium of the European LeukemiaNet with 18. Annual Symposium German Leukemia Competence Network

# PROGRAM

January 31 – February 1, 2017  
Congress Center Rosengarten Mannheim

Time	Gustav Mahler I Level 3		Gustav Mahler II Level 3		Gustav Mahler III Level 3		Alban Berg Level 3	
13:00 – 13:30	<b>Welcome and General Assembly</b>							
13:30 – 15:00	<b>CML (WP4)</b>		<b>MDS (WP8)</b>		<b>CLL / ERIC (WP7)</b>		<b>Chair: P. Ghia</b>	
		<b>Chair:</b> B. Simonsson / A Hochhaus			<b>Chair:</b> T. de Witte / P. Fenaux			
15'	EURO-SKI, updated analysis of predictors of TFR	S. Saußebe	5'	Welcome / Introduction	T. de Witte	10'	Welcome and introduction	P. Ghia
10'	Second stop study: NAUT	S. Saußebe	10'	Report EUMDS Registry SC meeting	T. de Witte / A. Smith	10'	Interpretation of karyotyping using mitogens vs. FISH vs. SNP-based array in CLL	A. Kater
15'	ELN recommendations	A. Hochhaus	10'	Progress of the Trial Platform: EMSCO and discussion of planned trial(s)	U. Platzbecker / P. Fenaux	10'	ERICLL Database	C. Moreno / A. Hadzidimitriou
12'	Cooperation on immune response analysis	S. Mustjoki						
12'	Randomized evaluation of IFN as maintenance after treatment discontinuation	A. Burchert	10'	Revision IWG 2006 criteria	P. Fenaux / U. Platzbecker	10'	Next Generation Sequencing	L. Sutton
12'	Prognostic role of transcript type analysis	M. Pffirmann	10'	Report of 9 <sup>th</sup> ELN MDS Flow working conference	A. v.d. Loosdrecht	10'	Cellular diagnosis and monitoring	A. Rawstron
12'	New options for standardization of molecular response analysis	N. Cross	20'	Progress of ongoing studies of EUMDS Registry	T. de Witte	10'	Update IG Certification Network	A. Hadzidimitriou / K. Stamatopoulos
			5'	FP7: progress of TRIAGE-MDS	J. Jansen			
2'	Suggestions for new topics / Next meeting		5'	Progress MDS-RIGHT (Horizon2020)	T. de Witte	10'	Update on the ERIC TP53 Network activities and TP53 certification (round 4 results)	S. Pospíšilová / J. Malčíková
			5'	HARMONY	G. Sanz	10'	1 <sup>st</sup> Global CLL Advocates Meeting	K. Stamatopoulos / A. Kater
			10'	Guidelines for allogeneic SCT in MDS	T. de Witte	10'		T. Zenz
						5'	The 1 000 cancer phenotype project	
15:00 – 15:30	<b>Coffee break (Foyer – Level 3)</b>							
15:30 – 16:15	<b>Joint meeting: Diagnostics (WP10), Cytogenetics (WP11), MRD (WP12) and NGS (WP13)</b>		<b>Coffee break (Foyer – Level 3)</b>		<b>Coffee break (Foyer – Level 3)</b>		<b>AML (WP5)</b>	
		<b>Chairs:</b> T. Haferlach / D. Haase / M.C. Béné						<b>Chairs:</b> G. Ossenkoppele
	In Memoriam: How David Grimwade influenced our work and paved the future					5'	AML Global Portal	G. Ossenkoppele
15'	How flow and PCR foster each other in AML	M.C. Béné				5'	World AML Awareness day	G. Ossenkoppele
15'	Can MRD improve outcome?	P. Valk				12'	Galinpepimut-S (GPS)- antiWT1- clinical trial in AML pts > 60 years in CR1	J. Janssen
15'	Targeted RNA Sequencing by NGS to identify unknown fusion partners and rare translocations	C. Haferlach				12'	Dendritic cell vaccin: PoC Phase IIa study in AML CR MRD+	A. v.d. Loosdrecht
						10'	International AML Platform Consortium Trial	A. Wei
16:15 – 17:00	<b>MRD (WP12) and NGS (WP13)</b>		<b>Diagnostics (WP 10)</b>		<b>Joint meeting: AML (WP5) and Diagnostics (WP10)</b>		<b>Cytogenetics (WP11)</b>	
		<b>Chair:</b> T. Haferlach			<b>Chairs:</b> M.C. Béné / G. Zini			<b>Chair:</b> H. Rieder
15'	HARMONY and NGS: What is needed now	J.M. Hernandez	20'	WP10 morphology faculty	G. Zini	15'	Flow cytometry part	G.J. Schuurhuis
15'	NGS-PTL: What we already achieved	G. Martinelli	20'	Harmonemia and beyond	M.C. Béné	15'	Molecular part	C. Thiede
15'	Genes, Panels, WES, WGS?	T. Haferlach				15'	Clinical part	G. Roboz
								15' TP53 and complex aberrations in MDS – not everything is clear
								15' 10 years of quality management in tumor cytogenetics
								15' Prognostication in AML based on karyotype and molecular mutations
17:00 – 17:30	<b>Coffee break (Foyer – Level 3)</b>							
17:30 – 19:00	<b>MPN (WP 9)</b>		<b>ALL (WP 6)</b>		<b>SCT (WP 14)</b>			
		<b>Chair:</b> T. Barbui			<b>Chair:</b> D. Hoelzer			<b>Chair:</b> D. Niederwieser
5'	Welcome	T. Barbui	15'	BCR-ABL like ALL, diagnostic, algorithm and new treatment options	S. Chiaretti	10'	Introduction (summary of activities of last year)	D. Niederwieser et al.
15'	The educational MPN project	F. Mc Mullin				15'	T cell prolymphocytic leukemia	W.W. Jedrzejczak
15'	A platform for European collaboration studies in MPN	A. Reiter	15'	PH+ ALL, experienced with de-escalation of chemotherapy	O. Gavrilova / E. Parovichnikova	15'	Treatment of progression / relapse in MM	G. Gahrton
15'	Markers of inflammation for clinical trials in MPN	G. Barosi	15'	Post-transplant imatinib: Final results of a randomized trial	O. Ottman	15'	HCT-CT study (recruitment, safety analysis)	D. Niederwieser et al.
15'	MPN CARE Settings and clinical trials	S. Koschmieder				10'	Project aiming at standardization of conditioning for transplantation	T. Ruutu
15'	ELN studies in venous thrombosis	T. Barbui	15'	Digital droplet PCR (ddPCR) for MRD monitoring	S. Chiaretti	10'	Global Survey 2013	D. Niederwieser
15'	JAK-NET project	A. Vannucchi	15'	Use of flow cytometry for risk-stratifying and to guide treatment pathways for adult T-LBL / ALL patients	B. Ostrowska / J. Walewski	10'	RIC versus Best Standard of Care in elderly patients with AML	D. Niederwieser
25'	Miscellaneous and discussion	All	15'	Educational efforts of EWALL	N. Goekbuget	10'	Proposal for Analysis EHA 2016 Proposal for presentations, proposal for chimerism analysis, how to reduce relapse incidence, MRD measurements	H.J. Kolb All